Susquehanna Fundamental Investments’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Susquehanna Fundamental Investments’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-60,125	Closed	-$2.48M	–	596
2025 Q4	$2.48M	Hold	60,125	–	–	0.08%	224
2025 Q3	$2.33M	Hold	60,125	–	–	0.09%	218
2025 Q2	$1.66M	Sell	60,125 -37,867	-39%	-$964K	0.04%	370
2025 Q1	$2.18M	Buy	+97,992	New	+$2.02M	0.03%	509
2020 Q4	–	Sell	-25,700	Closed	-$394K	–	1554
2020 Q3	$394K	Buy	+25,700	New	+$482K	0.01%	968

Other funds holding KNSA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Susquehanna Fundamental Investments's KNSA Position: Q1 2026 in Review

Susquehanna Fundamental Investments sold out of Kiniksa Pharmaceuticals (KNSA) in Q1 2026, closing a stake of 60,125 shares — an estimated $2.48M sold.

Susquehanna Fundamental Investments first reported a position in KNSA in Q3 2020 and held it in 5 quarters. The position peaked at $2.48M in Q4 2025. 228 funds tracked by Wall St. Rank hold KNSA as of Q1 2026.

Susquehanna Fundamental Investments reported no remaining Kiniksa Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Susquehanna Fundamental Investments sold 60,125 Kiniksa Pharmaceuticals shares in Q1 2026, an estimated $2.48M.
Susquehanna Fundamental Investments first reported a position in Kiniksa Pharmaceuticals in Q3 2020 and held it in 5 quarters.
Susquehanna Fundamental Investments's Kiniksa Pharmaceuticals position peaked at $2.48M in Q4 2025.
228 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2026.

Based on Susquehanna Fundamental Investments's 13F filing for Q1 2026, filed 15 May 2026.